Explore how disruptions in ASXL1 were correlated with better patient responses to immune checkpoint inhibition and long-term tumor control in model systems. (IMAGE)

St. Jude Children's Research Hospital

Explore how disruptions in ASXL1 were correlated with better patient responses to immune checkpoint inhibition and long-term tumor control in model systems.

Caption

(L to R) First author Tae Gun Kang, PhD, St. Jude Department of Immunology, senior co-corresponding author Caitlin Zebley, MD, PhD, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy and co-corresponding author Ben Youngblood, PhD, St. Jude Department of Immunology.

Credit

Courtesy of St. Jude Children's Research Hospital

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.